论文部分内容阅读
目的:验证血脂康对原发性肾病综合征(P.N.S)脂代谢、尿蛋白的影响;方法:60例P.N.S随机分成两组,服药前及服药后4周查血脂、尿蛋白、治疗组30例加服血脂康,疗程4周;结果:对照组与治疗组相比甘油三脂、胆固醇、尿蛋白均明显下降,分别为2.32±0.89和1.86±0.21,8.32±1.08和6.11±1.21,4.90±0.92和2.88±0.57,3.96±0.76和1.21±0.21,与治疗前相比,差异有显著性(P值均<0.05),对照组与治疗组各项观察指标治疗前后相比,P值<0.05差异显著;结论:血脂康对P.N.S的脂代谢及尿蛋白有一定作用。
Objective: To verify the effects of Xuezhikang on lipid metabolism and urinary protein in patients with primary nephrotic syndrome (PNS). Methods: Sixty PNS patients were randomly divided into two groups. Before treatment and 4 weeks after treatment, serum lipids and urine protein levels were examined in 30 patients The results showed that the triglyceride, cholesterol and urinary protein in the control group were significantly decreased compared with the treatment group (2.32 ± 0.89 and 1.86 ± 0.21, 8.32 ± 1.08 and 6.11 ± 1.21, 4.90 ± 0.92 and 2.88 ± 0.57, 3.96 ± 0.76 and 1.21 ± 0.21, respectively, which were significantly different from those before treatment (all P <0.05). Compared with the treatment group before and after treatment, P <0.05 The difference was significant; Conclusion: Xuezhikang PNS lipid metabolism and urine protein have a certain effect.